|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.670 USD | +11.33% |
|
-.--% | +221.15% |
| 06-01 | Revium Rx. Announces CFO Changes, Effective May 27, 2026 | CI |
| 05-15 | Revium Rx. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
Company Valuation: Revium Rx.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Market Cap 1 | 43.19 | 52.14 | 23.24 | 31.58 |
| Change | - | 20.71% | -55.43% | 35.91% |
| Enterprise Value (EV) 1 | 42.77 | 46.66 | 17.96 | 28.97 |
| Change | - | 9.1% | -61.51% | 61.33% |
| P/E Ratio | -34.5x | -64.5x | -11.7x | -2.35x |
| PBR | 107x | 9.5x | 1.29x | 4.59x |
| PEG | - | 1.4x | -0.2x | -0x |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -36x | -68.8x | -5.04x | -8.38x |
| EV / EBIT | -35.9x | -68.6x | -5.03x | -8.36x |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Dividend per Share 2 | - | - | - | - |
| Rate of return | - | - | - | - |
| EPS 2 | -0.0432 | -0.0233 | -0.0343 | -0.2215 |
| Distribution rate | - | - | - | - |
| Net sales | - | - | - | - |
| EBITDA 1 | -1.189 | -0.678 | -3.564 | -3.458 |
| EBIT 1 | -1.191 | -0.68 | -3.568 | -3.464 |
| Net income 1 | -1.213 | -0.683 | -3.505 | -13.45 |
| Net Debt 1 | -0.425 | -5.479 | -5.278 | -2.609 |
| Reference price 2 | 1.490 | 1.500 | 0.401 | 0.520 |
| Nbr of stocks (in thousands) | 28,988 | 34,757 | 57,929 | 60,729 |
| Announcement Date | 14/2/25 | 14/2/25 | 13/8/25 | 31/3/26 |
1USD in Million2USD
Estimates
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- RVRC Stock
- Valuation Revium Rx.
Select your edition
All financial news and data tailored to specific country editions
